To build near-term commercial opportunities, Agenus seeks to in-license immuno-oncology assets that complement and offer compelling combination therapy opportunities with our current portfolio, from preclinical to late stage development. We are also interested in platform technologies with the potential to enhance our capabilities to generate revenues from multiple product and combination product opportunities. For further information, please contact Business Development through ourĀ contact form.